Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer / Rimawi, M.F., de Angelis, C., Contreras, A., Pareja, F., Geyer, F.C., Burke, K.A., Herrera, S., Wang, T., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Chang, J.C., Krop, I.E., Wolff, A.C., Pavlick, A.C., Fuqua, S.A.W., Gutierrez, C., Hilsenbeck, S.G., Li, M.M., et al.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 167:3(2018), pp. 731-740. [10.1007/s10549-017-4533-9]
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
de Angelis C.Secondo
;
2018
Abstract
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
